Deucravacitinib captured roughly 68% PASI 90 response rates in pivotal trials and became the first oral TYK2 inhibitor approved for plaque psoriasis — yet Alumis is now reporting identical 68.0% PASI 90 figures from ONWARD1 at Week 24, with a PASI 100 of 41.0%, numbers that sit at the upper boundary of what the approved oral competition has shown and demand a serious comparison rather than a congratulatory read-through.
The clinical profile assembled across ONWARD1 and ONWARD2 carries a few design-level details worth examining. Quality-of-life improvements and itch relief preceded PASI 90 clearance, which is not a trivial sequence — it suggests envudeucitinib‘s mechanism is engaging symptom pathways before full plaque resolution, a pattern that has historically supported stronger patient-reported outcome labeling claims. More striking is the scalp psoriasis signal: over 30% of patients achieved clear or almost clear scalp by Week 4, climbing to roughly 75% by Week 24. Scalp disease is disproportionately distressing relative to body surface area involvement, and an early, durable response there carries real differentiation weight in a crowded oral market where deucravacitinib and the JAK inhibitors have uneven scalp data.
Alumis is burning approximately $81.5 million per quarter on R&D — down from $96.6 million a year ago as ONWARD enrollment closed — while holding $569.5 million in cash runway projected through Q4 2027. That timeline is deliberately tight around the NDA submission planned for Q4 2026 and the LUMUS Phase 2b SLE readout expected in Q3 2026. SLE is the genuine strategic leverage point here. If LUMUS topline data supports a pivotal design, envudeucitinib becomes a multi-indication TYK2 asset competing in a disease area where the standard of care remains deeply inadequate and no oral small molecule has established dominance. Alumis is also quietly disposing of lonigutamab, the anti-IL-31 receptor antibody it inherited through the ACELYRIN merger, signaling a deliberate consolidation around TYK2 rather than a diversified immunology portfolio.
The single data point that will define Alumis’s regulatory and commercial trajectory is the PASI 100 durability curve beyond Week 24 — specifically whether ONWARD3 long-term data, due in the second half of 2026, shows erosion of that 41% complete clearance rate or sustains it, because NDA label negotiations around maintenance claims hinge entirely on that number.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
